Benign Prostatic Hyperplasia (BPH) – Causes and Treatment
Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland that commonly affects older men and can obstruct urinary flow.
Wissenswertes über "Benign Prostatic Hyperplasia"
Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland that commonly affects older men and can obstruct urinary flow.
What is Benign Prostatic Hyperplasia?
Benign prostatic hyperplasia (BPH) is a non-cancerous, age-related enlargement of the prostate gland. The prostate is a walnut-sized gland located just below the bladder that surrounds the urethra. As the glandular tissue grows, it can compress the urethra, leading to difficulties with urination. BPH is one of the most common conditions affecting older men and becomes increasingly prevalent after the age of 50.
Causes
The exact causes of BPH are not fully understood. Key contributing factors include:
- Hormonal changes: As men age, the balance between androgens (particularly testosterone and dihydrotestosterone) and estrogens shifts, promoting prostate tissue growth.
- Aging: BPH occurs almost exclusively in older men, with risk increasing significantly after age 40.
- Genetic predisposition: A family history of BPH increases the likelihood of developing the condition.
- Lifestyle factors: Obesity, physical inactivity, and metabolic syndrome are discussed as contributing factors.
Symptoms
Symptoms of BPH result from the physical compression of the urethra and impaired bladder emptying. Common symptoms include:
- Frequent urge to urinate, including at night (nocturia)
- Weak or intermittent urine stream
- Difficulty starting urination
- Feeling of incomplete bladder emptying (residual urine)
- Dribbling after urination
- In severe cases: complete urinary retention (a medical emergency)
Diagnosis
BPH is diagnosed through a combination of assessments:
- Medical history and symptom scoring: The International Prostate Symptom Score (IPSS) is a standardized questionnaire used to assess symptom severity.
- Digital rectal examination (DRE): The physician palpates the prostate through the rectum to assess its size and consistency.
- Ultrasound (sonography): Used to measure prostate volume and assess residual urine in the bladder.
- Uroflowmetry: Measures urine flow rate to evaluate bladder emptying efficiency.
- PSA test (Prostate-Specific Antigen): A blood test used to rule out prostate cancer.
- Urinalysis: To exclude urinary tract infections or other conditions.
Treatment
Watchful Waiting
For men with mild symptoms and no complications, a watchful waiting approach may be appropriate. Lifestyle modifications such as reducing fluid intake in the evening, regular physical activity, and pelvic floor exercises can help manage symptoms.
Medication
- Alpha-1 blockers (e.g., tamsulosin, alfuzosin): Relax the smooth muscle of the prostate and bladder neck, improving urine flow.
- 5-alpha reductase inhibitors (e.g., finasteride, dutasteride): Block the conversion of testosterone to dihydrotestosterone, reducing prostate volume over time.
- Combination therapy: Both drug classes may be combined in more severe cases.
- PDE-5 inhibitors (e.g., tadalafil): Used when BPH is accompanied by erectile dysfunction.
Surgical and Minimally Invasive Procedures
- Transurethral resection of the prostate (TURP): The gold standard surgical treatment; excess prostate tissue is removed via the urethra.
- Laser procedures (e.g., holmium laser enucleation of the prostate, HoLEP): Less invasive alternatives to TURP with reduced bleeding risk.
- Open prostatectomy: Reserved for very large prostates; involves surgical removal of the enlarged tissue.
Complications
If left untreated, BPH can lead to serious complications, including:
- Acute urinary retention (sudden inability to urinate)
- Bladder stones
- Urinary tract infections
- Bladder dysfunction or overdistension
- Kidney damage due to urinary backflow (hydronephrosis)
References
- European Association of Urology (EAU): EAU Guidelines on Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), 2023.
- Oelke M. et al. - EAU Guidelines on the Treatment and Follow-up of Non-Neurogenic Male Lower Urinary Tract Symptoms. European Urology, 2013.
- Roehrborn CG. - Benign Prostatic Hyperplasia: An Overview. Reviews in Urology, 2005; 7 (Suppl 9): S3-S14.
Best-selling products
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, probiotic lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryThymosin Beta-4
Tesamorelin
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Cologne list
Calorie content
Related search terms: Benign Prostatic Hyperplasia + benign prostatic hyperplasia + BPH + benign prostate enlargement + prostatic hyperplasia